Tech Company Financing Transactions
IsoPlexis Funding Round
On 9/26/2017, IsoPlexis announced $13.5 million in Series B financing from Spring Mountain Capital, Connecticut Innovations and Ironwood Capital.
Transaction Overview
Company Name
Announced On
9/26/2017
Transaction Type
Venture Equity
Amount
$13,500,000
Round
Series B
Investors
Spring Mountain Capital (Lead Investor) (Gregory Ho)
Proceeds Purpose
This new funding will help us build on our momentum, and is a reflection of our investors' optimism around the IsoPlexis system.
Company Information
Company Status
Publicly-held
Industry
Software
Mailing Address
35 NE Industrial Rd.
Branford, CT 06405
USA
Branford, CT 06405
USA
Phone
Website
Email Address
Overview
Our proprietary single-cell multiplexing micro-immunoassay and software enable new therapeutic and diagnostic discovery opportunities. Single cell analysis facilitates determination of cellular subsets among heterogeneous cancer and immune cell populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
John Conley
Chairman
Rong Fan
Chief Executive Officer
Sean Mackay
Chief Financial Officer
John Strahley
Chief Scientific Officer
Jing Zhou
Vice President
Michael Kane
Vice President
Pat Paczkowski
Vice President
Cynthia Turcotte
VP - Bus. Development
Peter Siesel
VP - Engineering
Rui Zheng
VP - Human Resources
Carrie Carter
VP - Marketing
Jon Chen
VP - Product Management
Peter Tsiomplikas
VP - Sales
Verna Siu
Browse more venture capital transactions:
Prev: 9/26/2017: Opsidio venture capital transaction
Next: 9/26/2017: Hedron venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs